{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-019654","form_type":"8-K","ticker":"AKBA","cik":"0001517022","company_name":"Akebia Therapeutics, Inc.","filed_at":"2023-05-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.199062+00:00","generated_at":"2026-06-14T14:28:23.681118+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Akebia licenses Vafseo to Medice for Europe, Australia; $10M upfront, up to $100M milestones","bullets":["Medice gets exclusive rights to market Vafseo (vadadustat) for anemia in CKD dialysis patients in EEA, UK, Switzerland, Australia.","Akebia receives $10M upfront, up to $100M in commercial milestones, and tiered royalties of 10-30% of net sales.","Akebia retains 70% of net profit from non-dialysis population if it develops that indication; Medice commercializes both.","Vafseo approved in 33 countries; regulatory opinions expected in Switzerland and Australia later in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-019654","json":"https://secwatch.observer/filing/0001628280-23-019654.json","markdown":"https://secwatch.observer/filing/0001628280-23-019654.md","text":"https://secwatch.observer/filing/0001628280-23-019654.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1517022/000162828023019654/0001628280-23-019654-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1517022/000162828023019654/akba-20230524.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T14:28:23.681118+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d40d754f9cf91931a27bb7bc8093e85762f19e00","claim":"Akebia Therapeutics, Inc. entered into License Agreement with MEDICE Arzneimittel Pütter GmbH & Co. KG valued at $10 million (effective 2023-05-24).","evidence_excerpt":"On May 24, 2023 (the “Effective Date”), Akebia Therapeutics, Inc. (the “Company”) and MEDICE Arzneimittel Pütter GmbH & Co. KG (“Medice”) entered into a License Agreement (the “License Agreement”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517022/000162828023019654/0001628280-23-019654-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"MEDICE Arzneimittel Pütter GmbH & Co. KG"},{"label":"Value","value":"$10 million"},{"label":"Effective","value":"2023-05-24"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}